Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

6 januari 2022 uppdaterad av: Novo Nordisk A/S

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).

Studieöversikt

Status

Status

Indikerar aktuell rekryteringsstatus eller utökad åtkomststatus.
Avslutad

Betingelser

Betingelser

Sjukdomen, störningen, syndromet, sjukdomen eller skadan som studeras. På ClinicalTrials.gov kan tillstånd även innefatta andra hälsorelaterade frågor, såsom livslängd, livskvalitet och hälsorisker.

Intervention / Behandling

Intervention / Behandling

En process eller handling som är i fokus för en klinisk studie. Interventioner inkluderar läkemedel, medicinsk utrustning, procedurer, vacciner och andra produkter som antingen är undersökta eller redan tillgängliga. Interventioner kan också innefatta icke-invasiva tillvägagångssätt, såsom utbildning eller modifiering av kost och träning.

Studietyp

Studietyp

Beskriver arten av en klinisk studie. Studietyper inkluderar interventionsstudier (även kallade kliniska prövningar), observationsstudier (inklusive patientregister) och utökad tillgång.
Interventionell

Inskrivning (Faktisk)

Inskrivning

Antalet deltagare i en klinisk studie. Den "förväntade" registreringen är det antal deltagare som forskarna behöver för studien.
1264

Fas

Fas

Stadiet av en klinisk prövning som studerar ett läkemedel eller en biologisk produkt, baserat på definitioner utvecklade av U.S. Food and Drug Administration (FDA). Fasen baseras på studiens syfte, antal deltagare och andra egenskaper. Det finns fem faser: tidig fas 1 (tidigare listad som fas 0), fas 1, fas 2, fas 3 och fas 4. Ej tillämpligt används för att beskriva prövningar utan FDA-definierade faser, inklusive prövningar av enheter eller beteendeinterventioner.
  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Argentina
      • Caba, Argentina, C1060ABA
        • Novo Nordisk Investigational Site
      • Caba, Argentina, C1440AAD
        • Novo Nordisk Investigational Site
      • Cordoba, Argentina, 5000
        • Novo Nordisk Investigational Site
      • Córdoba, Argentina, 5008
        • Novo Nordisk Investigational Site
  • Bulgarien
      • Kozloduy, Bulgarien, 3320
        • Novo Nordisk Investigational Site
      • Razgrad, Bulgarien, 7200
        • Novo Nordisk Investigational Site
      • Sofia, Bulgarien, 1233
        • Novo Nordisk Investigational Site
      • Sofia, Bulgarien, 1618
        • Novo Nordisk Investigational Site
  • Förenta staterna
    • California
      • Concord, California, Förenta staterna, 94520
        • Novo Nordisk Investigational Site
      • Fresno, California, Förenta staterna, 93720
        • Novo Nordisk Investigational Site
      • Fullerton, California, Förenta staterna, 92835
        • Novo Nordisk Investigational Site
      • Lancaster, California, Förenta staterna, 93534
        • Novo Nordisk Investigational Site
      • Norco, California, Förenta staterna, 92860
        • Novo Nordisk Investigational Site
      • Sacramento, California, Förenta staterna, 95821
        • Novo Nordisk Investigational Site
      • Ventura, California, Förenta staterna, 93003
        • Novo Nordisk Investigational Site
      • Walnut Creek, California, Förenta staterna, 94598
        • Novo Nordisk Investigational Site
    • Colorado
      • Denver, Colorado, Förenta staterna, 80246
        • Novo Nordisk Investigational Site
      • Golden, Colorado, Förenta staterna, 80401
        • Novo Nordisk Investigational Site
    • Connecticut
      • Waterbury, Connecticut, Förenta staterna, 06708
        • Novo Nordisk Investigational Site
    • Florida
      • Boynton Beach, Florida, Förenta staterna, 33472
        • Novo Nordisk Investigational Site
      • Bradenton, Florida, Förenta staterna, 34201
        • Novo Nordisk Investigational Site
      • Fort Lauderdale, Florida, Förenta staterna, 33312
        • Novo Nordisk Investigational Site
      • Miami, Florida, Förenta staterna, 33174
        • Novo Nordisk Investigational Site
      • Tampa, Florida, Förenta staterna, 33634
        • Novo Nordisk Investigational Site
    • Georgia
      • Alpharetta, Georgia, Förenta staterna, 30022
        • Novo Nordisk Investigational Site
      • Lawrenceville, Georgia, Förenta staterna, 30046
        • Novo Nordisk Investigational Site
      • Roswell, Georgia, Förenta staterna, 30076
        • Novo Nordisk Investigational Site
    • Hawaii
      • Honolulu, Hawaii, Förenta staterna, 96814
        • Novo Nordisk Investigational Site
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Novo Nordisk Investigational Site
      • Peoria, Illinois, Förenta staterna, 61603
        • Novo Nordisk Investigational Site
      • Springfield, Illinois, Förenta staterna, 62711
        • Novo Nordisk Investigational Site
    • Indiana
      • Valparaiso, Indiana, Förenta staterna, 46383
        • Novo Nordisk Investigational Site
    • Iowa
      • West Des Moines, Iowa, Förenta staterna, 50266
        • Novo Nordisk Investigational Site
    • Kansas
      • Topeka, Kansas, Förenta staterna, 66606
        • Novo Nordisk Investigational Site
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40503
        • Novo Nordisk Investigational Site
      • Lexington, Kentucky, Förenta staterna, 40502
        • Novo Nordisk Investigational Site
    • Maryland
      • Rockville, Maryland, Förenta staterna, 20852
        • Novo Nordisk Investigational Site
    • Massachusetts
      • Waltham, Massachusetts, Förenta staterna, 02453
        • Novo Nordisk Investigational Site
      • Worcester, Massachusetts, Förenta staterna, 01655
        • Novo Nordisk Investigational Site
    • Nevada
      • Henderson, Nevada, Förenta staterna, 89052-2649
        • Novo Nordisk Investigational Site
      • Las Vegas, Nevada, Förenta staterna, 89148
        • Novo Nordisk Investigational Site
    • New Hampshire
      • Nashua, New Hampshire, Förenta staterna, 03063
        • Novo Nordisk Investigational Site
    • New York
      • Northport, New York, Förenta staterna, 11768
        • Novo Nordisk Investigational Site
      • West Seneca, New York, Förenta staterna, 14224
        • Novo Nordisk Investigational Site
    • North Carolina
      • Asheville, North Carolina, Förenta staterna, 28803
        • Novo Nordisk Investigational Site
      • Chapel Hill, North Carolina, Förenta staterna, 27514
        • Novo Nordisk Investigational Site
    • Ohio
      • Mentor, Ohio, Förenta staterna, 44060
        • Novo Nordisk Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104-5020
        • Novo Nordisk Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19140
        • Novo Nordisk Investigational Site
    • South Carolina
      • Greenville, South Carolina, Förenta staterna, 29605-4254
        • Novo Nordisk Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, Förenta staterna, 37404
        • Novo Nordisk Investigational Site
      • Chattanooga, Tennessee, Förenta staterna, 37411
        • Novo Nordisk Investigational Site
      • Nashville, Tennessee, Förenta staterna, 37212
        • Novo Nordisk Investigational Site
    • Texas
      • Amarillo, Texas, Förenta staterna, 79106
        • Novo Nordisk Investigational Site
      • Austin, Texas, Förenta staterna, 78731
        • Novo Nordisk Investigational Site
      • Austin, Texas, Förenta staterna, 78749
        • Novo Nordisk Investigational Site
      • Beaumont, Texas, Förenta staterna, 77701
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Förenta staterna, 75230
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Förenta staterna, 75226
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Förenta staterna, 75231
        • Novo Nordisk Investigational Site
      • Longview, Texas, Förenta staterna, 75605
        • Novo Nordisk Investigational Site
      • Pearland, Texas, Förenta staterna, 77584
        • Novo Nordisk Investigational Site
      • Round Rock, Texas, Förenta staterna, 78681
        • Novo Nordisk Investigational Site
    • Utah
      • Ogden, Utah, Förenta staterna, 84405
        • Novo Nordisk Investigational Site
    • Vermont
      • Bennington, Vermont, Förenta staterna, 05201
        • Novo Nordisk Investigational Site
      • South Burlington, Vermont, Förenta staterna, 05403
        • Novo Nordisk Investigational Site
    • Virginia
      • Chesapeake, Virginia, Förenta staterna, 23321
        • Novo Nordisk Investigational Site
      • Winchester, Virginia, Förenta staterna, 22601-3834
        • Novo Nordisk Investigational Site
    • Washington
      • Olympia, Washington, Förenta staterna, 98502
        • Novo Nordisk Investigational Site
      • Seattle, Washington, Förenta staterna, 98105
        • Novo Nordisk Investigational Site
      • Spokane, Washington, Förenta staterna, 99201
        • Novo Nordisk Investigational Site
    • Wisconsin
      • Green Bay, Wisconsin, Förenta staterna, 54303
        • Novo Nordisk Investigational Site
  • Grekland
      • Athens, Grekland, GR-11527
        • Novo Nordisk Investigational Site
      • Athens, Grekland, 115 25
        • Novo Nordisk Investigational Site
      • Ioannina, Grekland, 45500
        • Novo Nordisk Investigational Site
      • Larissa, Grekland, GR-41110
        • Novo Nordisk Investigational Site
      • Thessaloniki, Grekland, GR-54636
        • Novo Nordisk Investigational Site
      • Thessaloniki, Grekland, GR-57001
        • Novo Nordisk Investigational Site
      • Thessaloniki, Grekland, GR-54642
        • Novo Nordisk Investigational Site
      • Thessaloniki, Grekland, GR-54643
        • Novo Nordisk Investigational Site
  • Italien
      • Catanzaro, Italien, 88100
        • Novo Nordisk Investigational Site
      • Chieti, Italien, 66100
        • Novo Nordisk Investigational Site
      • Cittadella (PD), Italien, 35013
        • Novo Nordisk Investigational Site
      • Milano (MI), Italien, 20132
        • Novo Nordisk Investigational Site
      • Olbia, Italien, 07026
        • Novo Nordisk Investigational Site
      • Palermo, Italien, 90129
        • Novo Nordisk Investigational Site
  • Kanada
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2E1
        • Novo Nordisk Investigational Site
    • British Columbia
      • Victoria, British Columbia, Kanada, V8V 4A1
        • Novo Nordisk Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
        • Novo Nordisk Investigational Site
    • Ontario
      • Barrie, Ontario, Kanada, L4N 7L3
        • Novo Nordisk Investigational Site
      • Concord, Ontario, Kanada, L4K 4M2
        • Novo Nordisk Investigational Site
      • Etobicoke, Ontario, Kanada, M9R 4E1
        • Novo Nordisk Investigational Site
      • Hamilton, Ontario, Kanada, L8M 1K7
        • Novo Nordisk Investigational Site
      • Newmarket, Ontario, Kanada, L3Y 5G8
        • Novo Nordisk Investigational Site
      • Thunder Bay, Ontario, Kanada, P7A 4V7
        • Novo Nordisk Investigational Site
      • Toronto, Ontario, Kanada, M4G 3E8
        • Novo Nordisk Investigational Site
    • Quebec
      • Montreal, Quebec, Kanada, H4T 1Z9
        • Novo Nordisk Investigational Site
  • Korea, Republiken av
      • Bucheon, Korea, Republiken av, 14647
        • Novo Nordisk Investigational Site
      • Daegu, Korea, Republiken av, 42472
        • Novo Nordisk Investigational Site
      • Seongnam-si, Korea, Republiken av, 463-707
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republiken av, 02447
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republiken av, 03080
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republiken av, 04516
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republiken av, 06351
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republiken av, 08308
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republiken av, 137-701
        • Novo Nordisk Investigational Site
      • Wonju, Korea, Republiken av, 26426
        • Novo Nordisk Investigational Site
  • Kroatien
      • Karlovac, Kroatien, 47000
        • Novo Nordisk Investigational Site
      • Osijek, Kroatien, 31 000
        • Novo Nordisk Investigational Site
      • Varazdin, Kroatien, 42 000
        • Novo Nordisk Investigational Site
      • Zagreb, Kroatien, 10 000
        • Novo Nordisk Investigational Site
  • Polen
      • Bialystok, Polen, 15-435
        • Novo Nordisk Investigational Site
      • Skorzewo, Polen, 60-185
        • Novo Nordisk Investigational Site
      • Warsaw, Polen, 00-465
        • Novo Nordisk Investigational Site
      • Warsaw, Polen, 02-793
        • Novo Nordisk Investigational Site
      • Warszawa, Polen, 02-507
        • Novo Nordisk Investigational Site
      • Wroclaw, Polen, 50-381
        • Novo Nordisk Investigational Site
  • Puerto Rico
      • Ponce, Puerto Rico, 00716
        • Novo Nordisk Investigational Site
  • Rumänien
      • Brasov, Rumänien, 500101
        • Novo Nordisk Investigational Site
      • Brasov, Rumänien, 500283
        • Novo Nordisk Investigational Site
      • Bucharest, Rumänien, 13682
        • Novo Nordisk Investigational Site
    • Maramures
      • Baia Mare, Maramures, Rumänien, 430222
        • Novo Nordisk Investigational Site
    • Mures
      • Tirgu Mures, Mures, Rumänien, 540142
        • Novo Nordisk Investigational Site
    • Timis
      • Timisoara, Timis, Rumänien, 300125
        • Novo Nordisk Investigational Site
  • Ryska Federationen
      • Arkhangelsk, Ryska Federationen, 163045
        • Novo Nordisk Investigational Site
      • Kazan, Ryska Federationen, 420073
        • Novo Nordisk Investigational Site
      • Moscow, Ryska Federationen, 123448
        • Novo Nordisk Investigational Site
      • Penza, Ryska Federationen, 440026
        • Novo Nordisk Investigational Site
      • Saint Petersburg, Ryska Federationen, 194291
        • Novo Nordisk Investigational Site
      • Saint-Petersburg, Ryska Federationen, 194356
        • Novo Nordisk Investigational Site
      • Tumen, Ryska Federationen, 625023
        • Novo Nordisk Investigational Site
      • Voronezh, Ryska Federationen, 394018
        • Novo Nordisk Investigational Site
  • Serbien
      • Belgrade, Serbien, 11000
        • Novo Nordisk Investigational Site
      • Kragujevac, Serbien, 34000
        • Novo Nordisk Investigational Site
      • Nis, Serbien, 18000
        • Novo Nordisk Investigational Site
      • Novi Sad, Serbien, 21000
        • Novo Nordisk Investigational Site
      • Zajecar, Serbien, 19000
        • Novo Nordisk Investigational Site
  • Slovakien
      • Kosice, Slovakien, 040 01
        • Novo Nordisk Investigational Site
      • Kysucke Nove Mesto, Slovakien, 024 01
        • Novo Nordisk Investigational Site
      • Lubochna, Slovakien, 03491
        • Novo Nordisk Investigational Site
      • Lucenec, Slovakien, 984 01
        • Novo Nordisk Investigational Site
      • Zilina, Slovakien, 01001
        • Novo Nordisk Investigational Site
  • Spanien
      • Alcobendas, Spanien, 28100
        • Novo Nordisk Investigational Site
      • Almería, Spanien, 04001
        • Novo Nordisk Investigational Site
      • Girona, Spanien, 17007
        • Novo Nordisk Investigational Site
      • La Coruña, Spanien, 15006
        • Novo Nordisk Investigational Site
      • Pozuelo de Alarcon, Spanien, 28223
        • Novo Nordisk Investigational Site
      • Sabadell, Spanien, 08208
        • Novo Nordisk Investigational Site
      • Sevilla, Spanien, 41010
        • Novo Nordisk Investigational Site
      • Sevilla, Spanien, 41003
        • Novo Nordisk Investigational Site
  • Tjeckien
      • Hradec Kralove, Tjeckien, 500 05
        • Novo Nordisk Investigational Site
      • Plzen, Tjeckien, 30100
        • Novo Nordisk Investigational Site
      • Plzen, Tjeckien, 32600
        • Novo Nordisk Investigational Site
      • Trutnov, Tjeckien, 541 01
        • Novo Nordisk Investigational Site
  • Tyskland
      • Dresden, Tyskland, 01219
        • Novo Nordisk Investigational Site
      • Essen, Tyskland, 45136
        • Novo Nordisk Investigational Site
      • Falkensee, Tyskland, 14612
        • Novo Nordisk Investigational Site
      • Lingen, Tyskland, 49808
        • Novo Nordisk Investigational Site
      • Münster, Tyskland, 48145
        • Novo Nordisk Investigational Site
      • Saint Ingbert-Oberwürzbach, Tyskland, 66386
        • Novo Nordisk Investigational Site
      • Schweinfurt, Tyskland, 97421
        • Novo Nordisk Investigational Site
  • Ukraina
      • Dnipro, Ukraina, 49038
        • Novo Nordisk Investigational Site
      • Kharkiv, Ukraina, 61000
        • Novo Nordisk Investigational Site
      • Kyiv, Ukraina, 03049
        • Novo Nordisk Investigational Site
      • Lviv, Ukraina, 79010
        • Novo Nordisk Investigational Site
      • Ternopil, Ukraina, 46002
        • Novo Nordisk Investigational Site
      • Vinnytsia, Ukraina, 21010
        • Novo Nordisk Investigational Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Urvalskriterier

De nyckelkrav som personer som vill delta i en klinisk studie måste uppfylla eller de egenskaper de måste ha. Behörighetskriterier består av både inklusionskriterier (som krävs för att en person ska delta i studien) och uteslutningskriterier (som hindrar en person från att delta). Typer av behörighetskriterier inkluderar om en studie accepterar friska frivilliga, har ålders- eller åldersgruppskrav eller är begränsad av kön.

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble insulin combination is not considered a basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). - Subjects presently classified as being in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (Visit 1). - Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm

Deltagargrupp / Arm

En grupp eller undergrupp av deltagare i en klinisk prövning som får en specifik intervention/behandling, eller ingen intervention, enligt prövningens protokoll.
Intervention / Behandling

Intervention / Behandling

En process eller handling som är i fokus för en klinisk studie. Interventioner inkluderar läkemedel, medicinsk utrustning, procedurer, vacciner och andra produkter som antingen är undersökta eller redan tillgängliga. Interventioner kan också innefatta icke-invasiva tillvägagångssätt, såsom utbildning eller modifiering av kost och träning.
Experimentell: Faster aspart + insulin degludec with or without metformin
Läkemedel: Faster-acting insulin aspart
Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Läkemedel: Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Läkemedel: Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Aktiv komparator: NovoRapid/NovoLog + insulin degludec with or without metformin
Läkemedel: Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Läkemedel: Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Läkemedel: Insulin aspart
Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Vad mäter studien?

Primära resultatmått

Primära resultatmått

I en klinisk studies protokoll är det planerade utfallsmått som är det viktigaste för att utvärdera effekten av en intervention/behandling. De flesta kliniska studier har ett primärt utfallsmått, men vissa har mer än ett.
Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Glycosylated Haemoglobin (HbA1c)
Tidsram: Week 0, week 16
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16

Sekundära resultatmått

Sekundära resultatmått

I en klinisk studies protokoll, ett planerat utfallsmått som inte är lika viktigt som det primära utfallsmåttet för att utvärdera effekten av en intervention men som ändå är av intresse. De flesta kliniska studier har mer än ett sekundärt utfallsmått.
Resultatmått
Åtgärdsbeskrivning
Tidsram
Change From Baseline in 1-hour PPG Increment
Tidsram: Week 0, week 16
Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in 1,5-anhydroglucitol
Tidsram: Week 0, week 16
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in Fasting Plasma Glucose (FPG)
Tidsram: Week 0, week 16
Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No)
Tidsram: 16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No)
Tidsram: 16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test])
Tidsram: Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG [meal test]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
Week 0, week 16
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)
Tidsram: Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value.
Week 0, week 16
Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile
Tidsram: Week 0, week 16
Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)
Tidsram: Week 0, week 16
Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)
Tidsram: Week 0, week 16
Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile
Tidsram: Week 0, week 16
Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements
Tidsram: Week 0, week 16
Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No)
Tidsram: 16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No)
Tidsram: 16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Total Bolus Insulin Dose: in Units/Day
Tidsram: 16 weeks from randomisation
Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Bolus Insulin Dose: in Units/kg/Day
Tidsram: 16 weeks from randomisation
Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/Day
Tidsram: 16 weeks from randomisation
Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/kg/Day
Tidsram: 16 weeks from randomisation
Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units
Tidsram: 16 weeks from randomisation
Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units/kg
Tidsram: 16 weeks from randomisation
Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline
Tidsram: Week 0, week 16
Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Number of Treatment Emergent Adverse Events
Tidsram: Weeks 0-16
Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Injection Site Reactions
Tidsram: Weeks 0-16
Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall
Tidsram: Weeks 0-16

ADA classification of hypos:

  1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level.
  2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms.
  3. Asymptomatic: PG ≤3.9 mmol/L without symptoms.
  4. Probable symptomatic: No measurement with symptoms.
  5. Pseudo: PG >3.9 mmol/L with symptoms.
  6. Unclassifiable.

NN classification of hypos:

  1. BG confirmed: PG <3.1 mmol/L with/without symptoms.
  2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with symptoms.
  3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with/without symptoms.
  4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)
Tidsram: Weeks 0-16
Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
Tidsram: Weeks 0-16
Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal
Tidsram: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal
Tidsram: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal
Tidsram: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal
Tidsram: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Change From Baseline in Physical Examination
Tidsram: Week 0, week 16
Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central & Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin
Week 0, week 16
Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure
Tidsram: Week 0, week 16
Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Vital Signs: Pulse
Tidsram: Week 0, week 16
Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Electrocardiogram (ECG)
Tidsram: Week 0, week 16
Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Fundoscopy/Fundus Photography
Tidsram: Week 0, week 16
Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haematocrit
Tidsram: Week 0, week 16
Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haemoglobin
Tidsram: Week 0, week 16
Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Leukocytes
Tidsram: Week 0, week 16
Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Thrombocytes
Tidsram: Week 0, week 16
Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Erythrocytes
Tidsram: Week 0, week 16
Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT)
Tidsram: Week 0, week 16
Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alkaline Phosphatase
Tidsram: Week 0, week 16
Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST)
Tidsram: Week 0, week 16
Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Albumin
Tidsram: Week 0, week 16
Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Creatinine
Tidsram: Week 0, week 16
Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Potassium
Tidsram: Week 0, week 16
Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Sodium
Tidsram: Week 0, week 16
Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Bilirubin
Tidsram: Week 0, week 16
Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Protein
Tidsram: Week 0, week 16
Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Weight
Tidsram: Week 0, week 16
Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Mass Index (BMI)
Tidsram: Week 0, week 16
Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Sponsor

Den organisation eller person som initierar studien och som har auktoritet och kontroll över studien.
Novo Nordisk A/S

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

Studiestart

Det faktiska datumet då den första deltagaren registrerades i en klinisk studie. Det "förväntade" studiestartdatumet är det datum som forskarna tror kommer att vara studiens startdatum.
19 september 2017

Primärt slutförande (Faktisk)

Primärt slutförande

Det datum då den sista deltagaren i en klinisk studie undersöktes eller fick en intervention för att samla in slutliga data för det primära utfallsmåttet. Huruvida den kliniska studien avslutades enligt protokollet eller avslutades påverkar inte detta datum. För kliniska studier med mer än ett primärt utfallsmått med olika slutdatum avser denna term det datum då datainsamlingen är slutförd för alla primära utfallsmått. Det "förväntade" primära slutdatumet är det datum som forskarna tror kommer att vara det primära slutdatumet för studien.
7 januari 2019

Avslutad studie (Faktisk)

Avslutad studie

Det datum då den sista deltagaren i en klinisk studie undersöktes eller fick en intervention/behandling för att samla in slutliga data för de primära utfallsmåtten, sekundära utfallsmåtten och biverkningar (det vill säga den senaste deltagarens senaste besök). Det "förväntade" studiens slutdatum är det datum som forskarna tror kommer att vara studiens slutdatum.
29 januari 2019

Studieregistreringsdatum

Först inskickad

Först inskickad

Datumet då studiesponsorn eller utredaren först skickade in en studiepost till ClinicalTrials.gov. Det är vanligtvis en fördröjning på några dagar mellan det första inlämningsdatumet och postens tillgänglighet på ClinicalTrials.gov (det första publicerade datumet).
29 augusti 2017

Först inskickad som uppfyllde QC-kriterierna

Först inskickad som uppfyllde QC-kriterierna

Det datum då studiesponsorn eller utredaren först skickar in en studiepost som överensstämmer med National Library of Medicine (NLM) kvalitetskontroll (QC) granskningskriterier. Sponsorn eller utredaren kan behöva revidera och skicka in en studiepost en eller flera gånger innan NLM kvalitetskontrollkriterier uppfylls. Det är sponsorns eller utredarens ansvar att se till att studieposten överensstämmer med NLM QC-granskningskriterierna.
29 augusti 2017

Första postat (Faktisk)

Första postat

Datumet då studieposten först var tillgänglig på ClinicalTrials.gov efter granskning av National Library of Medicine (NLM) kvalitetskontroll (QC) har avslutats. Det är vanligtvis en fördröjning på några dagar mellan det datum då studiens sponsor eller utredare skickade in studieposten och det första publicerade datumet.
31 augusti 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

Senaste uppdatering publicerad

Det senaste datumet då ändringar i en studiepost gjordes tillgänglig på ClinicalTrials.gov. Det kan förekomma en fördröjning mellan när ändringarna skickades till ClinicalTrials.gov av studiens sponsor eller utredare (det senaste inlämningsdatumet för uppdateringen) och den senaste uppdateringen som publicerades.
11 januari 2022

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

Det senaste datumet då studiesponsorn eller utredaren lämnade in ändringar i en studiepost som överensstämmer med kvalitetskontrollkriterierna för National Library of Medicine (NLM). Det är sponsorns eller utredarens ansvar att se till att studieposten överensstämmer med NLM QC-granskningskriterierna.
6 januari 2022

Senast verifierad

Senast verifierad

Det senaste datumet då studiesponsorn eller utredaren bekräftade att informationen om en klinisk studie på ClinicalTrials.gov var korrekt och aktuell. Om en studie med rekryteringsstatus av rekrytering; inte rekryterar ännu; eller aktiv, inte rekrytering har inte bekräftats under de senaste 2 åren, studiens rekryteringsstatus visas som okänd.
1 januari 2022

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

Andra studie-ID-nummer

Identifierare eller ID-nummer andra än NCT-numret som tilldelats en klinisk studie av studiens sponsor, finansiärer eller andra. Dessa nummer kan innehålla unika identifierare från andra försöksregister och National Institutes of Health-bidragsnummer.
  • NN1218-4113
  • U1111-1180-0636 (Annan identifierare: World Health Organization (WHO))
  • 2016-000878-38 (Registeridentifierare: European Medicines Agency (EudraCT))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

Ja

IPD-planbeskrivning

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Cookie-inställningar

Vi använder cookies för att säkerställa att vi ger dig den bästa upplevelsen på vår webbplats. För mer information läs noggrant vår policy för sekretess och kakor. ...>>>Du kan när som helst ändra dina preferenser eller dra tillbaka ditt samtycke genom att radera kakorna från din webbplats eller dator enligt beskrivningen i policyn. Acceptera det och välj dina preferenser genom att markera motsvarande rutor i avsnittet "Hantera inställningar" nedan. Läs våra användarvillkor noga innan du fortsätter att använda någon del av denna webbplats.
«Hantera inställningar